Is QMS Medical overvalued or undervalued?

As of 14 August 2025, the valuation grade for QMS Medical has moved from very attractive to attractive, indicating a shift in market perception. The company is currently assessed as undervalued based on its financial metrics. Key ratios include a PE Ratio of 12.50, an EV to EBITDA of 8.20, and a PEG Ratio of 0.63, which suggest that the stock is trading at a discount compared to its earnings growth potential.
In comparison to its peers, QMS Medical stands out with a significantly lower PE Ratio than Poly Medicure, which has a PE of 53.86, and Blue Jet Health at 38.33. This positions QMS Medical favorably in the healthcare services sector, where many competitors are deemed very expensive. Despite the recent underperformance against the Sensex, with a year-to-date return of -33.85% compared to the Sensex's 4.17%, the company's attractive valuation metrics suggest potential for recovery and growth.